Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615235 · ClinicalTrials.gov registry record
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
A clinical trial of Kidney Diseases and Kidney Failure, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 18
- Study locations
NCT03615235 is a study of Kidney Diseases and Kidney Failure that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 5,000 participants, above the 1,654-participant average among 38 other Kidney Diseases trials with a reported enrollment target (202% higher). The trial reports 18 study locations across 14 states.
The verdict
NCT03615235, a study of Kidney Diseases and Kidney Failure, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 18
- Study locations
Study Summary
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
Conditions Studied
Study Locations (18)
New York
- Ichan School of Medicine at Mount Sinai - New York
- Columbia University Irving Medical Center - New York
- Weill Cornell Medicine - New York
Maryland
- University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
North Carolina
- Duke University - Durham
- Wake Forest School of Medicine - Winston-Salem
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Florida
- University of Miami / Miami Transplant Institute - Miami
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Joslin Diabetes Center / Harvard University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2027-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03615235
The ClinicalTrials.gov registry entry for NCT03615235 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,654-participant average among 38 other Kidney Diseases trials with a reported enrollment target (202% higher). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03615235 reports 18 study locations spanning 14 distinct geographic areas - top geographies include New York, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03615235 about?
NCT03615235 is a clinical study titled "APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)". The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in A...
What is the current status of trial NCT03615235?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2019-03-21. Estimated completion is 2027-05-30.
What conditions does trial NCT03615235 study?
This clinical trial studies the following conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic.
Who is sponsoring clinical trial NCT03615235?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03615235 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Supporting VETerans With Kidney Disease Through Food As Medicine
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.